Kymera Therapeutics

Biotech

Sanofi backs protein degrader after glimpse of clinical efficacy

In a small phase 1 trial, Kymera linked the IRAK4 candidate to improvements in symptoms, encouraging its partner Sanofi to take the program forward.
Nick Paul Taylor Dec 14, 2022 7:00am

Earnings arrive after dreadful 6 months, but readouts offer hope

Jul 18, 2022 9:42am

Kymera’s protein degrader shows potential to boost I-O

Nov 24, 2021 9:00am

Don't blink: PAQ gobbles up $30M series A to ink autophagy era

Jul 15, 2021 6:00am

Kymera, fresh off a $2B Sanofi pact, guns for an IPO

Aug 2, 2020 5:32am

Sanofi pays $150M upfront, $2B in biobucks for Kymera I&I deal

Jul 9, 2020 7:00am